Expanded Access Global Study for Loxo-292 - Title Pending
Research payments
$3,115,595
Through program year 2021, $3,115,595 in research payments was reported against Expanded Access Global Study for Loxo-292 - Title Pending, across 71 payments, paid by Eli Lilly and Company.
- Paid by
- Eli Lilly and Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $1,435,470 | 27 |
| 2020 | Research | $1,618,130 | 40 |
| 2019 | Research | $61,995 | 4 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Luis Raez Pembroke Pines, FL Named on 3 payments
- Lori Wirth Boston, MA Named on 3 payments
- Mark Socinski Orlando, FL Named on 3 payments
- Mykola Onyshchenko Torrance, CA Named on 3 payments
- Alexander Spira Fairfax, VA Named on 3 payments
- Christine Bestvina Chicago, IL Named on 2 payments
- Manisha Shah Columbus, OH Named on 2 payments
- Alexander Edward Drilon New York, NY Named on 2 payments
- John Morris Rochester, MN Named on 2 payments
- Nathan Pennell Cleveland, OH Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.